AP
NUVL

Antipodes Partners’s Nuvalent NUVL Stock Holding History

Antipodes Partners’s Portfolio NUVL Stock Details NUVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.2K Sell
275
-116
-30% -$11.8K ﹤0.01% 116
2025
Q4 		$39.3K Hold
391
– – ﹤0.01% 112
2025
Q3 		$33.8K Sell
391
-88
-18% -$6.96K ﹤0.01% 102
2025
Q2 		$36.5K Sell
479
-61
-11% -$4.46K ﹤0.01% 93
2025
Q1 		$38.3K Buy
+540
New +$42.2K ﹤0.01% 85

Other funds holding NUVL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Antipodes Partners's NUVL Position: Q1 2026 in Review

Antipodes Partners reduced its Nuvalent (NUVL) stake by 30% in Q1 2026, selling an estimated $11.8K and leaving 275 shares worth $28.2K. The position accounts for ﹤0.01% of the portfolio, ranked #116.

Antipodes Partners first reported a position in NUVL in Q1 2025 and has held it in 5 quarters since. The position peaked at $39.3K in Q4 2025. 263 funds tracked by Wall St. Rank hold NUVL as of Q1 2026.

  • Antipodes Partners held 275 shares of Nuvalent worth $28.2K as of Q1 2026.
  • Antipodes Partners sold 116 Nuvalent shares in Q1 2026, an estimated $11.8K.
  • Nuvalent made up ﹤0.01% of Antipodes Partners's portfolio in Q1 2026, its #116 holding.
  • Antipodes Partners first reported a position in Nuvalent in Q1 2025 and has held it in 5 quarters since.
  • Antipodes Partners's Nuvalent position peaked at $39.3K in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Nuvalent as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.